Epistaxis during treatment with paclitaxel

Nirit Yarom, Arnoldo Cyjon, Svetlana Kovel, Adelya Yachnin, Avishay Sella, Ella Evron

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The purpose of this study was to determine the incidence and severity of epistaxis in patients treated with paclitaxel. Patients who were treated with paclitaxel filled a questionnaire regarding their general health, medications and incidents of epistaxis. Relevant clinical information was obtained from the patients' charts. Forty-seven consecutive patients were recruited to the study. Twenty-four (51%) of the patients reported epistaxis during paclitaxel therapy. Twenty-three of 39 (59%) patients who received weekly paclitaxel had epistaxis at least once during treatment, compared with one out of eight patients who were treated every 3 weeks (P = 0.045). All episodes of epistaxis were mild, occurred with normal platelets counts and did not require blood product transfusions or treatment modification. The majority of the patients experienced the first episode of epistaxis on the third week of weekly paclitaxel treatment and then repeatedly throughout therapy. It is concluded that epistaxis is a common mild side-effect of weekly paclitaxel that has not been reported previously. In this trial, epistaxis did not have any major clinical consequences. However, when paclitaxel is combined with other drugs that may cause bleeding, such as bevacizumab, physicians should be alerted to the potential risk of this phenomenon.

Original languageEnglish
Pages (from-to)259-261
Number of pages3
JournalBasic and Clinical Pharmacology and Toxicology
Issue number3
StatePublished - Mar 2009
Externally publishedYes


Dive into the research topics of 'Epistaxis during treatment with paclitaxel'. Together they form a unique fingerprint.

Cite this